Filing summary
Entity mismatch: The supplied filing is Aquinox Pharmaceuticals, Inc.’s Form 10-Q, not a Neurogene Inc. filing. It covers the quarter ended March 31, 2019; the financial statements are unaudited.
Business context and reporting period
Aquinox is a development-stage pharmaceutical company. After its Phase 3 rosiptor trial failed in 2018, the company halted rosiptor development. At the filing date, it had no product candidates in clinical development or identified for clinical development and was evaluating strategic alternatives, including a merger, licensing or acquiring products, advancing research-stage compounds, or potentially returning capital and dissolving.
Financial performance and liquidity
| Metric | Q1 2019 | Q1 2018 / comparison |
|---|---|---|
| Revenue | None reported | No product revenue |
| Research and development expense | $0.1 million | $10.5 million |
| General and administrative expense | $2.6 million | $4.3 million |
| Total operating expenses | $2.7 million | $14.8 million |
| Other income, net | $0.5 million | $0.2 million |
| Net loss | $2.2 million | $14.6 million |
| Basic and diluted loss per share | $0.09 | $0.62 |
| Cash used in operating activities | $2.8 million | $15.6 million |
At March 31, 2019, cash and cash equivalents were $74.2 million, versus $76.9 million at year-end 2018; working capital was $71.2 million and accumulated deficit was $232.3 million. Management said existing resources should fund operations for at least 12 months, while anticipating a need for substantial future financing. The company reported no product revenue or profitability; operating margins are not meaningful in the absence of revenue.
Total liabilities were $3.9 million, including $0.5 million of operating lease liabilities and $0.004 million of other liabilities. No material debt balance was reported. The lease liability reflects adoption of the new lease accounting standard; adoption had no material impact on earnings or cash flows.
Material changes and unusual items
- Operating expenses and operating cash use fell substantially year over year, primarily following the rosiptor program halt and 2018 workforce restructurings.
- Following both restructurings, the workforce had declined from 56 employees to eight. The company expected at least $0.7 million of additional 2019 costs related to the November 2018 restructuring; $0.359 million remained expected at March 31, 2019. A separate July 2018 restructuring had estimated total costs of $9.390 million, of which $7.3 million had been paid by the report date.
- Q1 2019 other income was mainly interest income of $0.450 million. Cash equivalents included $50.2 million in U.S. government securities.
- On May 6, 2019, after quarter-end, the board approved executive agreement amendments tied to certain strategic alternatives and bonus arrangements. The filing says additional bonus multiples could be payable upon specified events or dates.
Outlook, commentary and risks
The filing provides no revenue or earnings guidance. Management’s stated runway estimate was at least 12 months, but it cautioned that actual cash needs could differ and additional financing might not be available on acceptable terms. The company’s future depends on identifying or acquiring product candidates or products; absent a suitable opportunity, the board could consider returning capital to stockholders and dissolving the business.
Key risks include having no clinical-stage pipeline or internal research and development capability, the challenge and potential dilution of acquisitions or a merger, limited cash and uncertain access to financing, and the possibility that restructuring has impaired the ability to rebuild capabilities. The company also disclosed unhedged foreign-currency exposure. Management reported disclosure controls were effective at a reasonable assurance level and no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Confirm the filing belongs to Aquinox Pharmaceuticals, Inc. (ticker AQXP), not Neurogene Inc.
- Verify the company’s strategic-alternatives process, including any merger, licensing, acquisition, capital return or dissolution developments.
- Assess cash burn, restructuring payments and liabilities against management’s at-least-12-month runway estimate.
- Review the terms and potential cost of the May 2019 executive amendments and bonuses.
- Confirm whether any product candidates have since been identified or advanced, given the absence of a clinical-development pipeline at the filing date.